Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII
- 1 December 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 102 (12) , 3919-3926
- https://doi.org/10.1182/blood-2003-01-0222
Abstract
Using separate adeno-associated viral 2 (AAV2) vectors to deliver the heavy and light chains of factor VIII (FVIII) we have overcome the packaging limitations of AAV, achieving phenotypic correction of hemophilia A in mice. AAV vectors were constructed that use a liver-specific promoter and the cDNA sequences of either the human or canine heavy and light chains of FVIII. After intraportal vein injection of these vectors in hemophilia-A mice, therapeutic to superphysiologic levels of active FVIII were achieved in plasma in a dose-dependent manner. Phenotypic correction of the bleeding diathesis was demonstrated by survival of all treated mice after tail clipping. Biochemical analysis demonstrated lower levels of heavy-chain (25- to 100-fold) compared with light-chain protein in the plasma of treated animals. Differences in gene transfer and transcription did not account for the differences in protein expression. We hypothesize that improvements in FVIII activity could be achieved by improvements in FVIII heavy-chain expression. This work demonstrates that cotransduction of liver with AAV vectors expressing the heavy and light chains of FVIII corrects hemophilia A in vivo, providing an alternative approach to the use of a single vector. This strategy may potentially be useful for other large therapeutic proteins that contain functionally distinct domains.Keywords
This publication has 40 references indexed in Scilit:
- 262. Preclinical Safety Testing of AAV-hFIX Vectors Purified by CsCl Centrifugation or Column ChromatographyMolecular Therapy, 2002
- Nonviral Transfer of the Gene Encoding Coagulation Factor VIII in Patients with Severe Hemophilia ANew England Journal of Medicine, 2001
- Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogsBlood, 2001
- Therapeutic levels of human factor VIII and IX using HIV-1–based lentiviral vectors in mouse liverBlood, 2000
- Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vectorBlood, 2000
- Advances toward Gene Therapy for Hemophilia at the MillenniumHuman Gene Therapy, 1999
- Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient miceProceedings of the National Academy of Sciences, 1999
- In Vivo Evaluation of an Adenoviral Vector Encoding Canine Factor VIII: High-Level, Sustained Expression in Hemophiliac MiceHuman Gene Therapy, 1999
- Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vectorNature Medicine, 1999
- Haemophilia prophylaxis in young patients–a long‐term follow‐upJournal of Internal Medicine, 1997